4h
Zacks Investment Research on MSNFDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib (Revised)Sanofi SNY announced that the FDA has accepted its regulatory filing seeking approval for its investigational BTK inhibitor ...
This Phase 2 trial aims to assess the safety, tolerability, and foralumab’s effect on microglial activation in patients with na-SPMS. Intranasal foralumab offers a novel approach to potentially ...
22h
Zacks Investment Research on MSNFDA Accepts Sanofi's Filing for Multiple Sclerosis Drug TolebrutinibSanofi SNY announced that the FDA has accepted its regulatory filing seeking approval for its investigational BTK inhibitor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results